| Literature DB >> 32318302 |
Virang Kumar1, Natario L Couser2,3,4, Arti Pandya5.
Abstract
Oculodentodigital dysplasia (ODDD) is a rare genetic disorder associated with a characteristic craniofacial profile with variable dental, limb, eye, and ocular adnexa abnormalities. We performed an extensive literature review to highlight key eye features in patients with ODDD and report a new case of a female patient with a heterozygous missense GJA1 mutation (c.65G>A, p.G22E) and clinical features consistent with the condition. Our patient presented with multiple congenital anomalies including syndactyly, microphthalmia, microcornea, retrognathia, and a small nose with hypoplastic alae and prominent columella; in addition, an omphalocele defect was present, which has not been reported in previous cases. A systematic review of the published cases to date revealed 91 literature reports of 295 individuals with ODDD. There were 73 different GJA1 mutations associated with these cases, of which the most common were the following missense mutations: c.605G>A (p.R202H) (11%), c.389T>C (p.I130T) (10%), and c.119C>T (p.A40V) (10%). Mutations most commonly affect the extracellular-1 and cytoplasmic-1 domains of connexin-43 (gene product of GJA1), predominately manifesting in microphthalmia and microcornea. The syndrome appears with an approximately equal sex ratio. The most common eye features reported among all mutations were microcornea, microphthalmia, short palpebral fissures, and glaucoma.Entities:
Year: 2020 PMID: 32318302 PMCID: PMC7165356 DOI: 10.1155/2020/6535974
Source DB: PubMed Journal: Case Rep Ophthalmol Med
Figure 1Facial photograph of a patient with oculodentodigital dysplasia; note the beaked nose with hypoplastic alae and prominent columella, microphthalmia, microcornea, small palpebral fissures, retrognathia.
Figure 2Complete syndactyly of the 4th and 5th digits of the right hand.
GJA1 variants without clinical information.
| Sources |
| Cases | |
|---|---|---|---|
| Nucleotide | Protein | ||
| Paznekas et al. [ | c.7G>A | p.D3N | 1 |
| Paznekas et al. [ | c.64G>A | p.G22R | 1 |
| Paznekas et al. [ | c.79T>C | p.S27P | 1 |
| Paznekas et al. [ | c.163A>G | p.N55D | 1 |
| Paznekas et al. [ | c.174A>C | p.Q58H | 1 |
| Paznekas et al. [ | c.175C>G | p.P59A | 1 |
| Paznekas et al. [ | c.221A>T | p.H74L | 1 |
| Paznekas et al. [ | c.428G>A | p.G143D | 1 |
| Paznekas et al. [ | c.430A>G | p.K144E | 1 |
| Paznekas et al. [ | c.434T>G | p.V145G | 1 |
| Paznekas et al. [ | c.442C>G | p.R148G | 1 |
| Paznekas et al. [ | c.578C>T | p.P193L | 1 |
Summary of sex distribution.
| Males | Females | Total | |||
|---|---|---|---|---|---|
| Individuals with clinical diagnosis of ODDD (with no molecular confirmation) | 14 | 45% | 18 | 56% | 32 |
|
| |||||
| Untested individuals with both ODDD phenotype and known relative with molecular confirmation | 52 | 53% | 46 | 47% | 98 |
|
| |||||
| Individuals with a molecular confirmed | 72 | 44% | 93 | 56% | 165 |
|
| |||||
| Totals | 138 | 47% | 157 | 53% | 295 |
Reported GJA1 mutations and sex distribution in ODDD.
| Sources | Multiple mutations? |
| Individuals with a molecular confirmed | Untested individuals with both ODDD phenotype and known relative with molecular confirmation | Total individuals with the ODDD phenotype | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nucleotide | Protein | Unspecified | Male | Female | Male | Female | Male | Female | Total | ||||
| Cavusoglu et al. 2019 | No | c.168_169insT | p.Q57SfsTer6 | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Aminabadi et al. 2009 & Aminabadi et al. 2010 | No | N/A | N/A | Missense mutation exon 2 (unspecified) | 1 | 0 | 2 | 1 | 3 | 75% | 1 | 25% | 4 |
| Dwarakanathan et al. 2015 & Furuta et al. 2012 | No | c.75G>T | p.W25C | N/A | 1 | 1 | 0 | 0 | 1 | 50% | 1 | 50% | 2 |
| Quick and Dobersen 2014; National Center for Biotechnology Information 2020 | Yes | c.605G>A | p.R202H | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| c.717G>A | p.R239R | ||||||||||||
| Paznekas et al. 2003 & Paznekas et al. 2009 | No | c.605G>A | p.R202H | N/A | 1 | 7 | 4 | 5 | 5 | 29% | 12 | 71% | 17 |
| Jamsheer et al. 2010 | Yes | c.301C>T | p.R101X | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| c.6delT | p.G2fsX7 | ||||||||||||
| Jamsheer et al. 2010 | No | c.301C>T | p.R101X | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Paznekas et al. 2009; Joss et al. 2008; & Richardson et al. 2006 | No | c.97C>T | p.R33X∗ | N/A | 0 | 2 | 0 | 0 | 0 | 0% | 2 | 100% | 2 |
| Paznekas et al. 2009; Richardson et al. 2004; Paznekas et al. 2003; & Gladwin et al. 1997 | No | c.93T>C | p.I31M | N/A | 0 | 0 | 4 | 4 | 4 | 50% | 4 | 50% | 8 |
| Wang et al. 2019 | No | c.91A>T | p.I311P | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Paznekas et al. 2009 & van Steensel et al. 2005 | No | c.780_781delTG | p.C260fsX306 | N/A | 1 | 2 | 0 | 0 | 1 | 33% | 2 | 67% | 3 |
| Paznekas et al. 2009; Paznekas et al. 2003; & Gorlin et al. 1963 | No | c.68A>C | p.K23T | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Dwarakanathan et al. 2015; Paznekas et al. 2009; & Vreeburg et al. 2007 | No | c.689_690delAT | p.Y230fsX236 | N/A | 0 | 3 | 1 | 0 | 1 | 25% | 3 | 75% | 4 |
| This study; Gumus 2018; Paznekas et al. 2009; Paznekas et al. 2003; & Traboulsi and Parks 1990 | No | c.65G>A | p.G22E | N/A | 0 | 3 | 0 | 0 | 0 | 0% | 3 | 100% | 3 |
| Wiest et al. 2006 | No | c.659C>A | p.S220Y | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Paznekas et al. 2009; Paznekas et al. 2003; & Norton et al. 1995 | No | c.646G>T | p.V216L | N/A | 1 | 0 | 4 | 1 | 5 | 83% | 1 | 17% | 6 |
| Park et al. 2017; Paznekas et al. 2009; & Paznekas et al. 2003 | No | c.61G>A | p.G21R | N/A | 0 | 2 | 0 | 0 | 0 | 0% | 2 | 100% | 2 |
| Brice et al. 2013 | No | c.617A>G | p.K206R | N/A | 1 | 2 | 1 | 1 | 2 | 40% | 3 | 60% | 5 |
| Paznekas et al. 2009 | No | c.602C>T | p.S201F | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Paznekas et al. 2009 & de la Parra et al. 2007 | No | c.5G>T | p.G2V | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Vitiello et al. 2005 & Vingolo et al. 1994 | No | c.581A>C | p.H194P∗ | N/A | 3 | 5 | 3 | 3 | 6 | 43% | 8 | 57% | 14 |
| Paznekas et al. 2009; Paznekas et al. 2003; & Judisch et al. 1979 | No | c.52T>C | p.S18P | N/A | 0 | 0 | 1 | 3 | 1 | 25% | 3 | 75% | 4 |
| Paznekas et al. 2009 & Paznekas et al. 2003 | No | c.50A>C | p.Y17S | N/A | 3 | 4 | 0 | 0 | 3 | 43% | 4 | 57% | 7 |
| Paznekas et al. 2009 & Debeer et al. 2005 | No | c.504_506delCTT | p.F169del | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Wiest et al. 2006 & Thomsen et al. 1998 | No | c.461C>A | p.T154N | N/A | 0 | 2 | 0 | 1 | 0 | 0% | 3 | 100% | 3 |
| Paznekas et al. 2009 & van Es et al. 2007 | No | c.460A>G | p.T154A∗ | N/A | 0 | 2 | 0 | 0 | 0 | 0% | 2 | 100% | 2 |
| Paznekas et al. 2009; Richardson et al. 2004; Paznekas et al. 2003; Gladwin et al. 1997; & Schrander-Stumpel et al. 1993 | No | c.443G>A | p.R148Q | N/A | 0 | 0 | 2 | 2 | 2 | 50% | 2 | 50% | 4 |
| Taşdelen et al. 2018 | No | c.442C>T | p.R148Ter | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Paznekas et al. 2009; Debeer et al. 2005; & Spaepen et al. 1991 | No | c.440Y>C | p.M147T | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Paznekas et al. 2009; Richardson et al. 2004; & Brueton et al. 1990 | No | c.427G>A | p.G143S | N/A | 0 | 0 | 8 | 1 | 8 | 89% | 1 | 11% | 9 |
| Orosz et al. 2018 | No | c.413G>A | p.G138D | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Paznekas et al. 2009; Paznekas et al. 2003; & Shapiro et al. 1997 | No | c.412G>C | p.G138R | N/A | 1 | 2 | 2 | 2 | 3 | 43% | 4 | 57% | 7 |
| Kogame et al. 2014 | No | c.412G>A | p.G138S | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Paznekas et al. 2009; Richardson et al. 2004; Paznekas et al. 2003; & Gladwin et al. 1997 | No | c.402G>T | p.K134N | N/A | 0 | 0 | 0 | 2 | 0 | 0% | 2 | 100% | 2 |
| Paznekas et al. 2009 & Paznekas et al. 2003 | No | c.400A>G | p.K134E | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Nishat et al. 2012; Paznekas et al. 2009; Paznekas et al. 2003; & Amador et al. 2008 | No | c.389T>C | p.I130T | N/A | 7 | 4 | 5 | 1 | 12 | 71% | 5 | 29% | 17 |
| Paznekas et al. 2009; Musa et al. 2008; Wiest et al. 2006; & Loddenkemper et al. 2002 | No | c.338T>C | p.L113P | N/A | 2 | 2 | 1 | 0 | 3 | 60% | 2 | 40% | 5 |
| Paznekas et al. 2009 & Debeer et al. 2005 | No | c.330G>C | p.E110D | N/A | 2 | 3 | 1 | 2 | 3 | 38% | 5 | 63% | 8 |
| Paznekas et al. 2009 & Kelly et al. 2006 | No | c.32T>C | p.L11P | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Gabriel et al. 2011 & Jamsheer et al. 2009 | No | c.31C>T | p.L11F | N/A | 0 | 2 | 0 | 0 | 0 | 0% | 2 | 100% | 2 |
| Porntaveetus et al. 2017 | No | c.31C>A | p.L11I | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Jamsheer et al. 2014 | No | c.317T>G | p.L106R | N/A | 2 | 0 | 0 | 0 | 2 | 100% | 0 | 0% | 2 |
| Paznekas et al. 2009 & Nivelon-Chevallier et al. 1981 | No | c.317T>C | p.L106P | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Paznekas et al. 2009 & Paznekas et al. 2003 | No | c.306G>C | p.K102N | N/A | 1 | 2 | 0 | 0 | 1 | 33% | 2 | 67% | 3 |
| Paznekas et al. 2009; Paznekas et al. 2003; & Wooldridge et al. 1977 | No | c.293A>G | p.Y98C | N/A | 1 | 3 | 1 | 1 | 2 | 33% | 4 | 67% | 6 |
| Paznekas et al. 2009 | No | c.287T>C | p.V96A | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Wiest et al. 2006 | No | c.287T>A | p.V96E | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Paznekas et al. 2009 & Kjaer et al. 2004 | No | c.286G>A | p.V96M | N/A | 2 | 2 | 0 | 0 | 2 | 50% | 2 | 50% | 4 |
| Paznekas et al. 2009 & Honkaniemi et al. 2005 | No | c.284A>G | p.H95R | N/A | 0 | 1 | 0 | 1 | 0 | 0% | 2 | 100% | 2 |
| Paznekas et al. 2009; Paznekas et al. 2003; & Opjordsmoen and Nyberg-Hansen 1980 | No | c.268C>G | p.L90V | N/A | 4 | 0 | 3 | 2 | 7 | 78% | 2 | 22% | 9 |
| Jamsheer et al. 2014 | No | c.257C>A | p.S86Y | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Pizzuti et al. 2004 | No | c.227G>A | p.R76H | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Izumi et al. 2013 | No | c.226C>T | p.R76C | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Paznekas et al. 2009; Paznekas et al. 2003; & Stanislaw et al. 1998 | No | c.226C>A | p.R76S | N/A | 0 | 2 | 0 | 2 | 0 | 0% | 4 | 100% | 4 |
| Choi et al. 2018 | No | c.221A>C | p.H74P∗ | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Paznekas et al. 2009; Richardson et al. 2004; Paznekas et al. 2003; & Gladwin et al. 1997 | No | c.206C>A | p.S69Y | N/A | 0 | 0 | 2 | 5 | 2 | 29% | 5 | 71% | 7 |
| Paznekas et al. 2009 & Vasconcellos et al. 2005 | No | c.176C>A | p.P59H | N/A | 4 | 4 | 1 | 0 | 5 | 56% | 4 | 44% | 9 |
| Paznekas et al. 2009 | No | c.145_147dupCAG | p.Q49dup | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Pazenkas et al. 2009; Paznekas et al. 2003; Weintraub et al. 1975; & Gellis and Feingold 1974 | No | c.154_156dupTTT | p.F52dup | N/A | 1 | 0 | 1 | 1 | 2 | 67% | 1 | 33% | 3 |
| Hadjichristou et al. 2017 & Paznekas et al. 2009 | No | c.146A>C | p.Q49P | N/A | 1 | 1 | 0 | 0 | 1 | 50% | 1 | 50% | 2 |
| Izumi et al. 2013 | No | c.145C>G | p.Q49E | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Paznekas et al. 2009 & Paznekas et al. 2003 | No | c.145C>A | p.Q49K | N/A | 3 | 2 | 0 | 0 | 3 | 60% | 2 | 40% | 5 |
| Amano et al. 2012; Feller et al. 2008; Paznekas et al. 2009; & Itro et al. 2005 | No | c.142G>A | p.E48K | N/A | 3 | 0 | 0 | 0 | 3 | 100% | 0 | 0% | 3 |
| Jamsheer et al. 2014 | No | c.139G>C | p.D47H | N/A | 0 | 3 | 0 | 0 | 0 | 0% | 3 | 100% | 3 |
| Tumminelli et al. 2016 | No | c.125G>C | p.E42Q | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Gabriel et al. 2011 | No | c.120delGGTTGAGTCAGC | p.V41_A44del | N/A | 0 | 1 | 1 | 2 | 1 | 25% | 3 | 75% | 4 |
| Paznekas et al. 2009 & Kellermayer et al. 2005 | Yes (compound heterozygous with | c.121G>C | p.V41L | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| N/A | p.R127H ( | ||||||||||||
| Park et al. 2019; Hayashi et al. 2014; Paznekas et al. 2009; Debeer et al. 2005; & Paznekas et al. 2003 | No | c.119C>T | p.A40V | N/A | 6 | 4 | 4 | 3 | 10 | 59% | 7 | 41% | 17 |
| Wittlieb-Weber et al. 2015 | No | c. 175C>T | p.P59S | N/A | 1 | 2 | 0 | 0 | 1 | 33% | 2 | 67% | 3 |
| Attig et al. 2016 | No | c.396_398delAAA | p.I132_K133delinsM | N/A | 3 | 2 | 0 | 0 | 3 | 60% | 2 | 40% | 5 |
| Paznekas et al. 2009 | No | c.19T>G | p.L7V | N/A | 1 | 0 | 0 | 0 | 1 | 100% | 0 | 0% | 1 |
| Himi et al. 2009 | No | c.13A>T | p.S5C | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| Pace et al. 2019 | No | c.287T>G | p.V96G | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 |
| No | c.77T>C | p.L26P | N/A | 0 | 1 | 0 | 0 | 0 | 0% | 1 | 100% | 1 | |
| Totals | 72 | 93 | 52 | 46 | 124 | 47% | 139 | 53% | 263 | ||||
∗Unknown which specific individuals tested.
Eye and ocular adnexa features reported in ODDD.
| Orbit | — | Microphthalmia (110/37%) | Hypotelorism (24/8%) | Hypertelorism (22/7%) | Short axial length (4/1%) | ||||||
| Anterior segment | Anterior chamber | Shallow anterior chamber (12/4%) | Deep anterior chambers (2/<1%) | ||||||||
| Cornea | Microcornea (111/38%) | Thick corneas (4/1%) | Corneal opacities (3/1%) | Corneal farinata (1/<1%) | Band keratopathy (1/<1%) | Corneal keratosis (1/<1%) | Abnormal Descemet's membrane (1/<1%) | Anteriorly deviated Schwalbe's line (1/<1%) | |||
| Sclera | Blue sclera (1/<1%) | ||||||||||
| Pupil | Persistent pupillary membranes (13/4%) | Eccentric pupils (3/1%) | |||||||||
| Lens | Cataracts (17/6%) | Lens opacities (2/<1%) | White retrolental masses (1/<1%) | ||||||||
| Uvea (iris, ciliary body) | Pale/atrophic irides (11/4%) | Uveitis (10/3%) | General iris abnormalities (7/2%) | Synechiae (4/1%) | Hypoplastic anterior iris stroma (3/1%) | Ciliary body cysts (2/<1%) | Flat iris (1/<1%) | Iridoschisis (1/<1%) | Inferior iris coloboma (1/<1%) | Dysplastic iris (1/<1%) | |
|
| |||||||||||
| Posterior segment | Uvea (choroid) | Thick choroid (2/<1%) | Thin choroid (1/<1%) | ||||||||
| Vitreous | Vitreous degeneration (1/<1%) | Vitreous membrane attachment to optic nerve and lens (1/<1%) | Persistent hyperplastic primary vitreous (1/<1%) | ||||||||
| Retina/fundus | Dysplastic retina/fundus (3/1%) | Pale retina/fundus (2/<1%) | Thread-like retinal vasculature (2/<1%) | Dystrophic retinal epithelium (1/<1%) | Hypoplastic macula (1/<1%) | Absent fundal glow with B-scan ultrasound (1/<1%) | |||||
| Optic disc | Pale/atrophic optic disc (3/1%) | Dysplastic optic disc (2/<1%) | Ellipsoid optic disc (1/<1%) | Optociliary vein presence (1/<1%) | Optic disc hypervascularity (1/<1%) | ||||||
|
| |||||||||||
| Ocular adnexa | Eyelid | Short/narrow palpebral fissures (56/19%) | Epicanthus (36/12%) | Telecanthus (11/4%) | Ptosis (7/2%) | Blepharophimosis (1/<1%) | Entropion (1/<1%) | Ectropion (1/<1%) | Epiblepharon (1/<1%) | Mucosal hypertrophy (1/<1%) | |
| Eyebrow/eyelash | Madarosis (19/6%) | Flared eyebrows (3/1%) (2 medially flared) | Synophyrs (1/<1%) | ||||||||
| Nasolacrimal duct | Nasolacrimal duct abnormalities (2/<1%) | Hypolacrimation (1/<1%) | |||||||||
|
| |||||||||||
| Other | Refractive errors | Myopia (16/5%) (2 anisometropic) | Hyperopia (8/3%) (2 anisometropic) | Astigmatism (1/<1%) | |||||||
| Eye movement disorders | Strabismus (27/9%) (9 esotropic, 1 exotropic) | Nystagmus (8/3%) | Amblyopia (3/1%) | Duane syndrome (2/<1%) | Brown syndrome (1/<1%) | ||||||
| Additional eye disorders | Glaucoma (51/17%) (4 closed-angle, 1 open-angle) | Paracentral scotoma (1/<1%) | |||||||||
| ERG/neurological | Abnormal ERG (2/<1%) | Delayed visual evoked responses (2/<1%) | Occipital subcortical white matter changes (1/<1%) | ||||||||
Common GJA1 mutations with associated eye features.
| Sources | Multiple mutations? |
| Individuals with | Associated eye features | |
|---|---|---|---|---|---|
| Nucleotide | Protein | Total | |||
| Quick and Dobersen 2014; National Center for Biotechnology Information 2020 | Yes | c.605G>A | p.R202H | 1 | Microphthalmia (1) |
| c.717G>A | p.R239R | ||||
|
| |||||
| Paznekas et al. 2009; Paznekas et al. 2003 | No | c.605G>A | p.R202H | 17 | Microphthalmia (1), microcornea (2) |
|
| |||||
| Nishat et al. 2012; Paznekas et al. 2009; Paznekas et al. 2003; and Amador et al. 2008 | No | c.389T>C | p.I130T | 17 | Microphthalmia (4), hypotelorism (6), cataract (1), pale/atrophic optic disc (1), and short palpebral fissures (4) |
|
| |||||
| Park et al. 2019; Hayashi et al. 2014; Paznekas et al. 2009; Debeer et al. 2005; and Paznekas et al. 2003 | No | c.119C>T | p.A40V | 17 | Microphthalmia (9), hypertelorism (3), hypotelorism (4), short axial length (4), cataract (1), microcornea (8), thick cornea (4), macular hypoplasia (1), shallow anterior chamber (4), myopia (4), strabismus (6) (1 esotropic), glaucoma (6), and epicanthus (3) |
Mutant connexin-43 domains and associated phenotype.
|
| Protein domain (amino acid range) (obtained from UniProt-P17302) | Associated phenotype (no. of individuals) |
|---|---|---|
| p.G2fsX7 (with p.R101X) | Cytoplasmic N-terminus(1-13) | Microcornea (7), microphthalmia (5), epicanthus (4), strabismus (3) (1 esotropic), short palpebral fissures (2), telecanthus (2), amblyopia (1), dysplastic fundus (1), optociliary vein (1), dysplastic optic disc (1), pale/atrophic optic disc (1), persistent pupillary membrane (1), myopia (3), hyperopia (1) (anisometropic), glaucoma (1), ptosis (1), entropion (1), madarosis (1), hypertelorism (1), and cataract (1) |
|
| ||
| p.W25C | Transmembrane-1 (14-36) | Microcornea (21), microphthalmia (14), short palpebral fissures (11), persistent pupillary membrane (6), madarosis (6), epicanthus (6), glaucoma (5), anterior iris stroma hypoplasia (3), hypertelorism (2), cataract (2), iris abnormalities (2), blonde fundus (1), iridoschisis (1), deep anterior chamber (1), hyperopia (2), strabismus (7) (3 esotropic), amblyopia (1), nystagmus (1), ptosis (1), epiblepharon (1), nasolacrimal duct obstruction (1), and flared eyebrows (1) (medially flared) |
|
| ||
| p.Q57SfsTer6 | Extracellular-1 (37-76) | Microphthalmia (32), microcornea (30), glaucoma (15) (2 closed-angle, 1 open-angle), hypertelorism (11), epicanthus (10), strabismus (9) (3 esotropic), short palpebral fissures (9), iris atrophy (peripupillary) (8), cataract (6), shallow anterior chamber (6), hypotelorism (5), short axial length (4), myopia (4), corneal farinata (4), telecanthus (3), iris abnormalities (2), eccentric pupils (2), persistent pupillary membrane (2), dysplastic fundus (1), dysplastic optic (1), macular hypoplasia (1), synechiae (1), ciliary body cysts (1), deep anterior chamber (1), hyperopia (1), ptosis (1), blepharophimosis (1), madarosis (1), nasolacrimal duct abnormalities (1), and low-voltage ERG (1) |
|
| ||
| p.Y98C | Transmembrane-2 (77-99) | Hypertelorism (5), microcornea (2), microphthalmia (3), glaucoma (3), strabismus (2) (1 esotropic), short palpebral fissures (2), eyelid mucosal hypertrophy (1), telecanthus (1), epicanthus (1), optic disc atrophy (1), hyperopia (1), myopia (1), strabismus (1), paracentral scotoma (1), madarosis (1), and delayed visual evoked potentials (1) |
|
| ||
| p.R101X (with p.G2fsX7) | Cytoplasmic-1 (100-154) | Microphthalmia (20), microcornea (18), short palpebral fissures (14), hypotelorism (14), glaucoma (9), myopia (7), epicanthus (5), cataract (3), strabismus (3), shallow anterior chamber (3), hypertelorism (2), opaque lens (1), optic disc hypervascularity (1), pale/atrophic optic disc (1), pale irides (1), iris abnormalities (2), astigmatism (1), Duane syndrome (1), ptosis (1), occipital subcortical white matter changes (1), and delayed visual evoked responses (1) |
|
| ||
| p.F169del | Transmembrane-3 (155-177) | Short palpebral fissures (1) |
|
| ||
| p.R202H (with p.R239R) | Extracellular-2 (178-208) | Microphthalmia (18), uveitis (8), glaucoma (8), microcornea (4), opaque cornea (2), thick choroid (2), cataract (1), shallow anterior chamber (1), nystagmus (2), and ptosis (1) |
|
| ||
| p.S220Y | Transmembrane-4 (209-231) | Microphthalmia (1), glaucoma (1), microcornea (1), and persistent pupillary membrane (1) |
|
| ||
| p.Y230fsX236 | Transmembrane-4 & cytoplasmic C-terminus (209-382) | Hypertelorism (2), hypotelorism (1), and flared eyebrows (2) (1 medially flared) |
|
| ||
| p.R239R (with p.R202H) | Cytoplasmic C-terminus(232-382) | Short palpebral fissures (3), epicanthus (2), hypotelorism (2), microcornea (2), pale irides (2), myopia (2), hyperopia (1) (1 anisometropic), corneal opacity (1), microphthalmia (1), retinal dysplasia (1), choroid thinning (1), glaucoma (1), madarosis (1), and loss of flash ERG (1) |
|
| ||
| Missense mutation exon 2 (unspecified) | Unknown | Microphthalmia (1), cataract (1), microcornea (1), uveitis (1), glaucoma (1), epicanthus (1), telecanthus (1), short palpebral fissures (1), and ptosis (1) |